NPPB and type 2 diabetes mellitus: After AVR, patients without T2D demonstrated an improvement in 6-minute walking distance (pre-AVR AS-noT2D, mean, 396 meters [95% CI, 365, 436] versus post-AVR AS-noT2D, mean, 434 meters [95% CI, 398, 472]; P=0.02) and a reduction in plasma NT-proBNP levels (pre-AVR AS-noT2D, 377 ng/L [181–2039] versus post-AVR AS-noT2D, 302 ng/L [210–652]; P=0.04).